| First Author | Ohkawa Y | Year | 2021 |
| Journal | Cancer Sci | Volume | 112 |
| Issue | 9 | Pages | 3756-3768 |
| PubMed ID | 34145699 | Mgi Jnum | J:312910 |
| Mgi Id | MGI:6792959 | Doi | 10.1111/cas.15032 |
| Citation | Ohkawa Y, et al. (2021) Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model. Cancer Sci 112(9):3756-3768 |
| abstractText | High expression of gangliosides GD3 and GD2 is observed in human gliomas. The functions of GD3 and GD2 in malignant properties have been reported in glioma cells in vitro, but those functions have not yet been investigated in vivo. In this study, we showed that deficiency of GD3 synthase (GD3S, St8sia1) attenuated glioma progression and clinical and pathological features in a platelet-derived growth factor B-driven murine glioma model. Lack of GD3S resulted in the prolonged lifespan of glioma-bearing mice and low-grade pathology in generated gliomas. Correspondingly, they showed reduced phosphorylation levels of Akt, Erks, and Src family kinases in glioma tissues. A DNA microarray study revealed marked alteration in the expression of various genes, particularly in MMP family genes, in GD3S-deficient gliomas. Re-expression of GD3S restored expression of MMP9 in primary-cultured glioma cells. We also identified a transcription factor, Ap2alpha, expressed in parallel with GD3S expression, and showed that Ap2alpha was critical for the induction of MMP9 by transfection of its cDNA and luciferase reporter genes, and a ChIP assay. These findings suggest that GD3S enhances the progression of gliomas by enhancement of the Ap2alpha-MMP9 axis. This is the first report to describe the tumor-enhancing functions of GD3S in vivo. |
